Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19
Muneerah M Aleissa, Emily A. Silverman, Luisa M. Paredes Acosta, et al.
Antimicrobial Agents and Chemotherapy (2020) Vol. 65, Iss. 1
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 382
Therapeutic potential of pyrrole and pyrrolidine analogs: an update
N. Jeelan Basha, S. M. Basavarajaiah, K. Shyamsunder
Molecular Diversity (2022) Vol. 26, Iss. 5, pp. 2915-2937
Open Access | Times Cited: 115
Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative
Hector Bonilla, Michael J. Peluso, Kathleen E. Rodgers, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 58
Potential herb–drug interactions between anti-COVID-19 drugs and traditional Chinese medicine
Ling Ye, Shicheng Fan, Pengfei Zhao, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 9, pp. 3598-3637
Open Access | Times Cited: 26
Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment
Jiashu Xie, Zhengqiang Wang
Acta Pharmaceutica Sinica B (2021) Vol. 11, Iss. 6, pp. 1607-1616
Open Access | Times Cited: 45
In vitro inhibition and molecular docking of a new ciprofloxacin‐chalcone against SARS‐CoV‐2 main protease
Rania Alaaeldin, Muhamad Mustafa, Gamal El‐Din A. Abuo‐Rahma, et al.
Fundamental and Clinical Pharmacology (2021) Vol. 36, Iss. 1, pp. 160-170
Open Access | Times Cited: 41
New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
Robert L. Atmar, Natalie Finch
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 8
Open Access | Times Cited: 34
The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy
Guyi Wang, Bing Xiao, Jiayi Deng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 33
Polymeric nanoparticles as therapeutic agents against coronavirus disease
Letícia Emiliano Charelli, Gabriela C. Mattos, Ariane de Jesus Sousa‐Batista, et al.
Journal of Nanoparticle Research (2022) Vol. 24, Iss. 1
Open Access | Times Cited: 28
Plitidepsin: a Repurposed Drug for the Treatment of COVID-19
Miguel Ángel Martı́nez
Antimicrobial Agents and Chemotherapy (2021) Vol. 65, Iss. 4
Open Access | Times Cited: 37
Late remdesivir treatment initiation partially protects African green monkeys from lethal Nipah virus infection
Emmie de Wit, Brandi N. Williamson, Friederike Feldmann, et al.
Antiviral Research (2023) Vol. 216, pp. 105658-105658
Open Access | Times Cited: 13
Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project
Jason M. Devgun, Rongmei Zhang, Jeffrey Brent, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e2255815-e2255815
Open Access | Times Cited: 12
Heterocyclic compounds as antiviral drugs: Synthesis, structure–activity relationship and traditional applications
Giovanny Carvalho dos Santos, Lucas Michelão Martins, Bruna Andressa Bregadiolli, et al.
Journal of Heterocyclic Chemistry (2021) Vol. 58, Iss. 12, pp. 2226-2260
Closed Access | Times Cited: 31
Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study
Khalid Al Sulaiman, Ohoud Aljuhani, Abdulrahman I. Al Shaya, et al.
Critical Care (2021) Vol. 25, Iss. 1
Open Access | Times Cited: 30
Current treatment strategies for COVID‑19 (Review)
Fabin Han, Yanming Liu, Mei Mo, et al.
Molecular Medicine Reports (2021) Vol. 24, Iss. 6
Open Access | Times Cited: 29
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19
Tomáš Cihlář, Richard L. Mackman
Antiviral Therapy (2022) Vol. 27, Iss. 2, pp. 135965352210827-135965352210827
Open Access | Times Cited: 21
Remdesivir significantly reduces SARS‐CoV‐2 viral load on nasopharyngeal swabs in hospitalized patients with COVID‐19: A retrospective case–control study
Annalucia Biancofiore, Antonio Mirijello, Maria Alessandra Puteo, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 5, pp. 2284-2289
Open Access | Times Cited: 18
Machine Learning as a Precision-Medicine Approach to Prescribing COVID-19 Pharmacotherapy with Remdesivir or Corticosteroids
Carson Lam, Anna Siefkas, Nicole S. Zelin, et al.
Clinical Therapeutics (2021) Vol. 43, Iss. 5, pp. 871-885
Open Access | Times Cited: 22
Remdesivir: Quo vadis?
Erik De Clercq
Biochemical Pharmacology (2021) Vol. 193, pp. 114800-114800
Open Access | Times Cited: 19
An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19)
Pasquale Pagliano, Carmine Sellitto, Giuliana Scarpati, et al.
Expert Opinion on Drug Discovery (2021) Vol. 17, Iss. 1, pp. 9-18
Open Access | Times Cited: 18
The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion
Ting‐Hsu Chen, May‐Jywan Tsai, Chun‐Sheng Chang, et al.
Journal of Infection and Public Health (2022) Vol. 16, Iss. 1, pp. 42-54
Open Access | Times Cited: 13
Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study
Andrea Carta, Claudio Conversano
BMC Health Services Research (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 16
Real-life experience with remdesivir for treatment of COVID-19 among older adults: a multicentre retrospective study
Ili Margalit, Giusy Tiseo, Marco Ripa, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 6, pp. 1505-1509
Open Access | Times Cited: 6
Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease
Gusti Putu Wahyunanda Crista Yuda, Naufa Hanif, Adam Hermawan
DARU Journal of Pharmaceutical Sciences (2023) Vol. 32, Iss. 1, pp. 47-65
Closed Access | Times Cited: 5
Pulmonary delivery of remdesivir and dexamethasone encapsulated nanostructured lipid carriers for enhanced inflammatory suppression in lung
Chian‐Wei Chen, Chun‐Ping Chang, Yi-Shuan Wen, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 90, pp. 105144-105144
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top